These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26346174)

  • 1. Cognitive Impairments in LRRK2-Related Parkinson's Disease: A Study in Chinese Individuals.
    Zheng Y; Pei Z; Liu Y; Zhou H; Xian W; Fang Y; Chen L; Wu Q
    Behav Neurol; 2015; 2015():621873. PubMed ID: 26346174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intact working memory in non-manifesting LRRK2 carriers--an fMRI study.
    Thaler A; Helmich RC; Or-Borichev A; van Nuenen BF; Shapira-Lichter I; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T; Mirelman A;
    Eur J Neurosci; 2016 Jan; 43(1):106-12. PubMed ID: 26536050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease.
    Ben Sassi S; Nabli F; Hentati E; Nahdi H; Trabelsi M; Ben Ayed H; Amouri R; Duda JE; Farrer MJ; Hentati F
    Parkinsonism Relat Disord; 2012 Mar; 18(3):243-6. PubMed ID: 22056842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson's disease.
    Lin CH; Wu RM; Tai CH; Chen ML; Hu FC
    Parkinsonism Relat Disord; 2011 Feb; 17(2):84-8. PubMed ID: 21167764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
    Estanga A; Rodriguez-Oroz MC; Ruiz-Martinez J; Barandiaran M; Gorostidi A; Bergareche A; Mondragon E; Lopez de Munain A; Marti-Masso JF
    Parkinsonism Relat Disord; 2014 Oct; 20(10):1097-100. PubMed ID: 25127457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and behavioral symptoms in Parkinson's disease patients with the G2019S and R1441G mutations of the LRRK2 gene.
    Somme JH; Molano Salazar A; Gonzalez A; Tijero B; Berganzo K; Lezcano E; Fernandez Martinez M; Zarranz JJ; Gómez-Esteban JC
    Parkinsonism Relat Disord; 2015 May; 21(5):494-9. PubMed ID: 25840672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
    Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
    Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants.
    Oosterveld LP; Allen JC; Ng EY; Seah SH; Tay KY; Au WL; Tan EK; Tan LC
    Neurology; 2015 Sep; 85(12):1039-42. PubMed ID: 26311745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Confirmation of LRRK2 S1647T variant as a risk factor for Parkinson's disease in southern China.
    Zheng Y; Liu Y; Wu Q; Hong H; Zhou H; Chen J; Wang H; Xian W; Li J; Liu Z; Pei Z; Chen L
    Eur J Neurol; 2011 Mar; 18(3):538-40. PubMed ID: 20629711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
    Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
    Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive profile of LRRK2-related Parkinson's disease.
    Srivatsal S; Cholerton B; Leverenz JB; Wszolek ZK; Uitti RJ; Dickson DW; Weintraub D; Trojanowski JQ; Van Deerlin VM; Quinn JF; Chung KA; Peterson AL; Factor SA; Wood-Siverio C; Goldman JG; Stebbins GT; Bernard B; Ritz B; Rausch R; Espay AJ; Revilla FJ; Devoto J; Rosenthal LS; Dawson TM; Albert MS; Mata IF; Hu SC; Montine KS; Johnson C; Montine TJ; Edwards KL; Zhang J; Zabetian CP
    Mov Disord; 2015 Apr; 30(5):728-33. PubMed ID: 25650144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain-derived neurotrophic factor (BDNF) genetic polymorphism greatly increases risk of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease.
    Liu J; Zhou Y; Wang C; Wang T; Zheng Z; Chan P
    Parkinsonism Relat Disord; 2012 Feb; 18(2):140-3. PubMed ID: 21924942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olfactory dysfunction in sporadic Parkinson's Disease and LRRK2 carriers.
    Johansen KK; Warø BJ; Aasly JO
    Acta Neurol Scand; 2014 May; 129(5):300-6. PubMed ID: 23937295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers.
    Bregman N; Thaler A; Mirelman A; Helmich RC; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N;
    Brain Struct Funct; 2017 Apr; 222(3):1207-1218. PubMed ID: 27401793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of association between LRRK2 G2385R and cognitive dysfunction in Korean patients with Parkinson's disease.
    Hong JH; Kim YK; Park JS; Lee JE; Oh MS; Chung EJ; Kim JY; Sung YH; Lyoo CH; Lee JH; Kwon DY; Kim HS; Shin HW; Park SA; Park IS; Kim JS; Lee PH; Koh SB; Baik JS; Kim SJ; Ma HI; Kim JW; Kim YJ
    J Clin Neurosci; 2017 Feb; 36():108-113. PubMed ID: 27839916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
    Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subclinical signs in LRRK2 mutation carriers.
    Johansen KK; White LR; Farrer MJ; Aasly JO
    Parkinsonism Relat Disord; 2011 Aug; 17(7):528-32. PubMed ID: 21641848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
    Yahalom G; Orlev Y; Cohen OS; Kozlova E; Friedman E; Inzelberg R; Hassin-Baer S
    Mov Disord; 2014 Jul; 29(8):1057-60. PubMed ID: 24903616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
    Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
    Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 R1628P contributes to Parkinson's disease susceptibility in Chinese Han populations from mainland China.
    Yu L; Hu F; Zou X; Jiang Y; Liu Y; He X; Xi J; Liu L; Liu Z; He L; Xu Y
    Brain Res; 2009 Nov; 1296():113-6. PubMed ID: 19699188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.